Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen

Coherus Oncology (NASDAQ:CHRS) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

Separately, Oppenheimer initiated coverage on Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Coherus Oncology presently has a consensus rating of “Hold” and a consensus target price of $5.51.

Coherus Oncology Trading Down 3.6%

NASDAQ:CHRS opened at $1.63 on Friday. The company has a 50-day moving average price of $1.81 and a 200-day moving average price of $1.56. Coherus Oncology has a 12 month low of $0.71 and a 12 month high of $2.62. The company has a current ratio of 1.47, a quick ratio of 1.23 and a debt-to-equity ratio of 0.61. The stock has a market cap of $244.32 million, a price-to-earnings ratio of 1.12 and a beta of 1.04.

Coherus Oncology (NASDAQ:CHRS) last announced its quarterly earnings results on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. The company had revenue of $12.75 million for the quarter, compared to analysts’ expectations of $14.09 million. Equities analysts predict that Coherus Oncology will post -1.05 EPS for the current year.

Hedge Funds Weigh In On Coherus Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in CHRS. CWM LLC boosted its position in shares of Coherus Oncology by 13.8% in the 4th quarter. CWM LLC now owns 40,334 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 4,902 shares in the last quarter. ProShare Advisors LLC grew its stake in shares of Coherus Oncology by 36.3% in the 4th quarter. ProShare Advisors LLC now owns 24,718 shares of the biotechnology company’s stock worth $35,000 after buying an additional 6,583 shares during the last quarter. Jefferies Financial Group Inc. increased its position in Coherus Oncology by 2.5% during the 3rd quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 8,000 shares in the last quarter. Corient Private Wealth LLC increased its position in Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 10,000 shares in the last quarter. Finally, Tejara Capital Ltd raised its stake in Coherus Oncology by 1.7% during the second quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after buying an additional 11,552 shares during the last quarter. Institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.